Prime Movers Lab Rundown: Gilgamesh Signs $2B Deal with AbbVie & Lyten Delivers Li-S Batteries
Prime Movers Lab portfolio companies hit significant milestones in May, including Gilgamesh signing a blockbuster deal with AbbVie that could be worth as much as $2 billion. Elsewhere in our portfolio, Lyten delivered samples of its 6.5 Ah lithium-sulfur cells to Stellantis and other leading US and EU automotive OEMs. Media attention on Elon Musk’s Neuralink also brought considerable interest to other major players in the brain computer interface sector, including portfolio company Paradromics. Read these stories and more below:
- FierceBiotech: AbbVie inks $2B-plus next-gen neuro deal with Gilgamesh (Gilgamesh)
- Electrek: Stellantis is about to test the first-ever production-line lithium-sulfur batteries (Lyten)
- Wired: Elon Musk’s Neuralink Had a Brain Implant Setback. It May Come Down to Design (Paradromics)
- Bloomberg: Venture Capital Cash Fuels Space Startup Dreams (Prime Movers Lab and Space Perspective)
- Bloomberg: Designer of World’s Tallest Building Wants to Turn Skyscrapers Into Batteries (Energy Vault)
- Forbes: What You Need To Know About Brain-Computer Interfaces (Paradromics)
- Longevity.Technology: Morphoceuticals is on a mission to create a new field of bioelectromics with ‘extraordinary’ regenerative potential (Morphoceuticals)
Prime Movers Lab invests in breakthrough scientific startups founded by Prime Movers, the inventors who transform billions of lives. We invest in companies reinventing energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.
Sign up here if you are not already subscribed to our blog.
